News and Trends 23 Feb 2023 Moderna and Life Edit Therapeutics look to speed up gene editing therapies Moderna, Inc., a biotechnology company working on messenger RNA (mRNA) therapeutics and vaccines, and Life Edit Therapeutics Inc., an ElevateBio company focused on gene editing technologies and therapeutics, have announced a strategic research and development collaboration to discover and develop in vivo mRNA gene editing therapies. The partnership will combine Life Edit’s suite of proprietary […] February 23, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 10 Feb 2023Beyond Biotech podcast 33: Astellas Pharma, Innovation Agency Lithuania, 4basebio This week, our guests are Romualda Stragienė, director at Innovation Agency Lithuania and Andrius Sliuzas, export key account manager of high tech industries at Innovation Agency Lithuania; 4basebio CEO Heikki Lanckriet; and Yoshitsugu Shitaka, chief scientific officer at Astellas. 4basebio 4basebio, a spinout of 2Invest AG in 2020, is a life sciences company engaged in […] February 10, 2023 Share WhatsApp Twitter Linkedin Email
News and Trends 7 Feb 2023 AAHI bags $9.9M to develop nasal spray influenza RNA vaccine The Access to Advanced Health Institute (AAHI) has been awarded a project agreement worth up to $9.9 million through the Medical CBRN Defense Consortium (MCDC) Other Transaction Authority (OTA) to develop a prototype intranasal bivalent influenza RNA vaccine candidate. The candidate will be based on AAHI’s self-amplifying RNA (saRNA) platform, which targets both pandemic A(H5N1) […] February 7, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Feb 2023 Cancer Genomics: Technological innovation set to fuel research breakthroughs By Neil Ward, vice President and general manager, PacBio EMEA We’ve known for a long time that genomic sequencing can strengthen our understanding of cancer’s highly complex and variable pathology. But to date, embedding genomics into cancer research has been challenging because of limitations in sequencing technology. But with recent innovations, this is changing. Genomic […] February 1, 2023 - 3 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jan 2023 Lupus treatment hope from Japanese miRNA research A group of researchers from the Graduate School of Medicine at Nagoya University in Japan have discovered the impact of microRNA (miRNA) on inflammation in lupus in mice. They identified two miRNAs that are downregulated in the disease and an uncommon situation that occurs in which multiple miRNAs regulate the same set of genes. Although […] January 26, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Interview 23 Jan 2023 Watch: pHion Therapeutics talks about next-generation mRNA vaccines pHion Therapeutics is a U.K.-based vaccine development company. It is developing a pipeline of therapeutic and prophylactic vaccines focussed on viral infections and oncology. The company’s proprietary RALA platform can deliver anionic molecules, such as mRNA and DNA, in a stealth-like way, evading detection, to generate a potent antigen-specific CD8+ T-cell response. The RALA peptide-based […] January 23, 2023 - 1 minutemin - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2023 AbbVie bets on Anima mRNA modulators to tackle cancer AbbVie and Anima Biotech have announced a collaboration to discover and develop mRNA biology modulators for three targets in oncology and immunology. Anima Biotech will use its mRNA Lightning platform to discover novel mRNA biology modulators against the collaboration targets, providing AbbVie exclusive rights to license and further develop and commercialize the programs. “This collaboration […] January 11, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jan 2023 BioNTech partnering with UK Government on personalized mRNA cancer immunotherapies BioNTech SE has signed a memorandum of understanding (MoU) with the Government of the United Kingdom. The deal is set to benefit patients by speeding up clinical trials for personalized mRNA immunotherapies. The aim is to provide personalized cancer therapies for up to 10,000 patients by the end of 2030, either through clinical trials or […] January 6, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jan 2023 2023 Editorial Calendar updated Each month here at Labiotech.eu, we produce a special newsletter. While still news-related, these special editions are an opportunity to take a deeper look at topics of interest. It also allows us to focus on some of the special awareness days – of which there are many – associated with health and the life sciences. […] January 5, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Dec 2022 Ethris and DIOSynVax to develop mRNA betacoronavirus vaccine Ethris GmbH is to collaborate with U.K.-based DIOSynVax to jointly develop a protective mRNA vaccine candidate against a broad range of betacoronaviruses. The efforts will utilize Ethris’ mRNA modification and design technologies as well as its lipidoid nanoparticle (LNP) and stabilization platforms. The collaboration is founded on a $42 million award to DIOSynVax by the […] December 21, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 Dec 2022 Providence Therapeutics’ mRNA rabies vaccine hits milestone Providence Therapeutics Holdings Inc. says its new mRNA vaccine program for rabies post-exposure prophylaxis has achieved a preclinical proof-of-concept milestone. The candidate was developed in partnership with Everest Medicines utilizing Providence’s clinically validated mRNA technology platform. “We are pleased to demonstrate that Providence’s mRNA technology supports development of additional products that fight a number of […] December 16, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2022 ExPLoRNA Therapeutics receives mRNA technology funding ExPLoRNA Therapeutics, a Polish biotech company working on mRNA vaccines and therapeutics, has received funding from the Bill & Melinda Gates Foundation to further develop its mRNA technology. ExPLoRNA specializes in novel cap analogs, the starting part of mRNA crucial for enabling successful production of the encoded protein. ExPLoRNA’s technology increases protein production beyond the […] December 7, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email